论文部分内容阅读
背景与目的表皮生长因子受体酪氨酸激酶抑制剂(epidermal growth factor receptor tyrosine kinase in-hibitor,EGFR-TKI)治疗非小细胞肺癌(non-small cell lung cancer,NSCLC)有效的临床预测指标包括:女性、亚裔、无吸烟史、腺癌类型以及产生皮疹等,本研究的目的是探寻吉非替尼治疗无进展生存期(progression-free survival,PFS)6个月的NSCLC患者的临床预后因素。方法 2005年1月-2010年3月我组经治80例吉非替尼治疗PFS6个月的NSCLC病例,分析其临床特点与PFS的相关性。结果年龄>70岁、更早的分期(IIIb)、非骨转移患者显示出更长的中位PFS(27个月vs12个月;32个月vs12个月;16个月vs10个月,P<0.05)。ECOG-PS评分0分-1分较2分-3分者、既往化疗周期数多于4周期或化疗PFS长于6个月者较化疗不足4周期或缓解6个月者的吉非替尼中位PFS似乎更长(15个月vs10个月;16个月vs12个月;14个月vs12个月),但差异无统计学意义(P>0.05)。服药后出现皮疹及皮疹II度以上者的中位PFS较无皮疹或皮疹0度-I度者更长(16个月vs13个月,P=0.17;19个月vs11个月,P=0.085),但差异无统计学意义。性别、吸烟指数、病理类型、除骨以外的转移部位、初治或复治等因素与吉非替尼治疗长期获益患者的PFS无关(P>0.05)。结论年龄>70岁、更早的分期(IIIb)岁、非骨转移患者进行吉非替尼治疗可能获得较长的PFS。
Background and objective Effective clinical predictors for the treatment of non-small cell lung cancer (NSCLC) with epidermal growth factor receptor tyrosine kinase in-hibitor (EGFR-TKI) include: : Female, Asian, Non-smoking History, Types of Adenocarcinoma and Skin Rash, etc. The purpose of this study was to explore the clinical outcomes of gefitinib in progression-free survival (PFS) for 6 months in NSCLC patients factor. Methods From January 2005 to March 2010, 80 cases of gefitinib treated with PFS for 6 months in our hospital were analyzed retrospectively. The correlation between clinical features and PFS was analyzed. Results Patients aged> 70 years and older (IIIb), patients with non-bone metastases showed longer median PFS (27 months vs 12 months; 32 months vs 12 months; 16 months vs 10 months, P < 0.05). ECOG-PS score of 0 points -1 points compared with 2 points -3 points, the number of previous cycles of chemotherapy more than 4 cycles or chemotherapy PFS longer than 6 months less chemotherapy 4 cycles or 6 months of gefitinib The PFS seemed longer (15 months versus 10 months; 16 months vs. 12 months; 14 months vs. 12 months), but the difference was not statistically significant (P> 0.05). Median PFS with a rash and rash of more than 1 degree after medication was longer than 0 degrees-I without rash or rash (16 months vs 13 months, P = 0.17; 19 months vs 11 months, P = 0.085) , But the difference was not statistically significant. Gender, smoking index, pathological type, metastasis sites other than bone, initial treatment or retreatment were not related to PFS of gefitinib in long-term benefit (P> 0.05). Conclusions Age> 70 years and earlier stage (IIIb), patients with non-bone metastases may receive longer PFS for gefitinib therapy.